Medisca v. FlackTek: Six-Patent SpeedMixer Dispute Dismissed With Prejudice
Medisca Pharmaceutique and Medisca, Inc. brought a six-patent infringement action against FlackTek and its manufacturing and SpeedMixer subsidiaries in South Carolina, targeting compounding mixer technology used across pharmaceutical, personal care, and cannabis applications. After 568 days of litigation, both sides agreed to a stipulated dismissal with prejudice — each bearing its own costs.
A Six-Patent SpeedMixer Battle Settled Into Permanent Silence
Filed on 12 October 2023 in the District of South Carolina before Judge Jacquelyn D. Austin, this case saw Medisca Pharmaceutique, Inc. and Medisca, Inc. assert six United States patents — US10993876B2, US11090224B2, US10420705B2, US10231903B2, US10765600B2, and US11096864B2 — against FlackTek, Inc., FlackTek Manufacturing, Inc., and FlackTek Speedmixer, Inc. The patents cover compounding mixer systems and related technology, products relevant to pharmaceutical compounding, personal care, cosmetics, and cannabis preparation markets.
On 2 May 2025, the parties filed a stipulated dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), terminating all pending claims with prejudice. The with-prejudice designation is significant: Medisca is permanently barred from re-asserting the same claims against FlackTek on the same accused products. The fee arrangement — each party bearing its own costs — is consistent with a negotiated resolution rather than a unilateral capitulation by either side.
The 568-day duration, spanning from filing through to stipulated dismissal, suggests the parties engaged in meaningful litigation activity — likely including early discovery and potentially claim construction briefing — before reaching a resolution. The public record does not disclose the terms of any underlying commercial agreement, licensing arrangement, or covenant not to sue that may have accompanied the dismissal. Whether Medisca secured any licensing value or FlackTek obtained a freedom-to-operate assurance remains unknown from the docket alone.
Filing to Dismissed with Prejudice in 568 days
568 days — above the median for district-level patent cases resolved short of trial
Dismissed with prejudice: what the stipulated exit means for both parties
Rule 41 stipulated dismissal — a bilateral, negotiated exit
A dismissal under Rule 41(a)(1)(A)(ii) requires the consent of all parties, distinguishing it from a unilateral withdrawal. The with-prejudice designation means the court’s dismissal operates as a final judgment on the merits for claim-preclusion purposes. Medisca cannot re-file these specific claims against FlackTek on the same accused products in any federal court.
Permanent bar on re-filingMedisca exits permanently — six patents remain in force but this dispute is closed
A with-prejudice dismissal forecloses Medisca from reviving these claims against FlackTek. However, all six asserted patents remain active and enforceable against third parties. The mutual cost-bearing arrangement suggests Medisca likely received some form of consideration — potentially a license, design-around commitment, or covenant — though no such terms are disclosed on the public docket.
Patents remain enforceable vs. othersFlackTek secures permanent closure — but underlying IP exposure persists
FlackTek, FlackTek Manufacturing, and FlackTek Speedmixer obtain a permanent bar against Medisca re-asserting these six patents on the accused SpeedMixer products. The mutual cost-bearing arrangement and consensual nature of the dismissal suggest FlackTek avoided an adverse merits ruling. Any private agreement governing future product freedom is not reflected in the public record.
No merits adjudicationSpeedMixer IP landscape remains live — six patents still enforceable against the market
For competitors and distributors in pharmaceutical compounding mixer markets, Medisca’s six patents are unimpaired and available for future enforcement actions. The SpeedMixer technology implicated spans pharma compounding, personal care, cosmetics, and cannabis — broad commercial exposure. Companies sourcing or distributing similar centrifugal mixing equipment should assess FTO exposure against this patent family independently of this case’s resolution.
Third-party FTO risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Medisca Pharmaceutique, Inc. | Company | Pharmaceutical compounding supplier — holder of US10993876B2 and 5 related mixer patentsSearch in Eureka ↗ |
| Co-Plaintiff | Medisca, Inc. | Company | Search in Eureka ↗ |
| Defendant | Flacktek, Inc. | Company | SpeedMixer manufacturer and distributor serving pharmaceutical, cosmetic, and cannabis marketsSearch in Eureka ↗ |
| Co-Defendant | Flacktek Manufacturing, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Flacktek Speedmixer, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Daniel C. Cooley | Attorney | Counsel for Medisca Pharmaceutique, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Jordan | Attorney | Counsel for Medisca Pharmaceutique, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jason Alan Pittman | Attorney | Counsel for Medisca Pharmaceutique, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Parmanand K. Sharma | Attorney | Counsel for Medisca Pharmaceutique, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Dority & Manning PA | Law Firm | Representing Medisca Pharmaceutique, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Finnegan, Henderson, Farabow, Garrett & Dunner LLP | Law Firm | Representing Medisca Pharmaceutique, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Finnegan Henderson Farabow Garrett And Dunner, LLP (Reston) | Law Firm | Representing Medisca Pharmaceutique, Inc.Search in Eureka ↗ |
| Defendant counsel | Sara Centioni Kanos. | Attorney | Counsel for Flacktek, Inc.Search in Eureka ↗ |
| Defendant law firm | Maynard Nexsen PC | Law Firm | Representing Flacktek, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jacquelyn D Austin | Judge | South Carolina District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal language — ‘dismissed, with prejudice’ pursuant to Rule 41(a)(1)(A)(ii) — represents a consensual, bilateral termination carrying the legal weight of a final judgment for claim-preclusion purposes. Critically, no merits ruling was issued: no patent was found valid or invalid, infringed or not infringed. The equal cost-bearing provision reinforces that neither party secured a clear litigation win, and the resolution almost certainly reflects a private commercial agreement whose terms are shielded from the public record.
US10993876B2 — pharmaceutical compounding SpeedMixer systems
The six asserted patents — US10993876B2, US11090224B2, US10420705B2, US10231903B2, US10765600B2, and US11096864B2 — cover centrifugal mixing technology used in pharmaceutical compounding, personal care product preparation, and cannabis formulation. Filed across US15 and US16 application series, the patents reflect a multi-generation continuation strategy building incremental protection over mixer design, container engagement, drive systems, and compounding methods. The breadth of application numbers suggests deliberate portfolio construction to cover both apparatus and method claims.
In the pharmaceutical compounding market, SpeedMixer-type centrifugal technology is a widely adopted platform across independent compounding pharmacies, hospital pharmacy systems, and contract manufacturing organisations. Medisca’s decision to assert six patents simultaneously against FlackTek — the market’s primary SpeedMixer brand — signals that this portfolio is positioned as a structural barrier to entry, not merely a single product defence. For sector participants, the survival of all six patents post-dismissal means the enforcement risk profile is unchanged and potentially signals future third-party campaigns.
Should you run an FTO against US10993876B2 and the Medisca mixer patent family?
Any company manufacturing, importing, distributing, or integrating centrifugal mixing systems for pharmaceutical compounding, personal care, or cannabis preparation should treat this six-patent family as a live FTO concern. The with-prejudice dismissal in Medisca v. FlackTek resolves only that bilateral dispute — it creates no precedent, no invalidity finding, and no public license that third parties can rely upon. Contract manufacturers supplying SpeedMixer-compatible accessories or formulation services are equally exposed.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of all six Medisca patents, identify continuation and divisional family members not asserted in this case, and surface prior art landscapes that inform invalidity arguments. Eureka’s portfolio heat-mapping tools let R&D teams visualise overlap between their mixer product specifications and the independent claims across this family — enabling faster, more defensible design-around decisions before product launch.
Run a freedom-to-operate analysis on US10993876B2 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical compounding equipment patent cases in US district courts
Explore patent infringement actions involving pharmaceutical compounding and mixing equipment technology filed in South Carolina and neighbouring US district courts.
What this case signals for the pharmaceutical compounding mixer IP landscape
Six-patent enforcement campaigns in niche equipment sectors signal portfolio depth — and the terms of exit matter as much as the filing.
With-prejudice exits don’t extinguish the patent — only the named dispute
All six Medisca patents survive this dismissal fully enforceable. Companies distributing, importing, or manufacturing functionally similar centrifugal mixing systems for pharmaceutical compounding, cosmetics, or cannabis applications face live infringement exposure. A dismissal with prejudice against one defendant tells competitors nothing about their own risk profile.
Six-patent campaigns raise the cost and complexity of defence significantly
Medisca’s decision to assert six patents simultaneously — across multiple application numbers and priority dates — substantially increases the cost and complexity of any invalidity or non-infringement defence. This multi-patent strategy is consistent with portfolio enforcement designed to accelerate resolution, and the 568-day timeline suggests it achieved that aim.
Medisca v Flacktek — key questions answered
The case was dismissed with prejudice by stipulation of all parties on 2 May 2025, after 568 days of litigation. No merits ruling was issued. Both parties agreed to bear their own attorneys’ fees and costs, consistent with a negotiated private resolution.
Medisca asserted six patents: US10993876B2, US11090224B2, US10420705B2, US10231903B2, US10765600B2, and US11096864B2. These patents cover centrifugal mixing systems and methods for pharmaceutical compounding, personal care, and cannabis applications, targeting FlackTek’s SpeedMixer product line.
No. A dismissal with prejudice under Rule 41 carries no validity or infringement finding. All six Medisca patents remain active and fully enforceable against third parties. The dismissal only bars Medisca from re-asserting these specific claims against FlackTek on the accused products.
When both parties agree to bear their own costs in a with-prejudice dismissal, it typically suggests a bilateral exchange of value rather than one party’s capitulation. This is consistent with a private settlement involving a license, covenant not to sue, or commercial agreement — though no such terms are disclosed on the public docket.
Yes. The resolution of Medisca v. FlackTek does not diminish the enforceability of Medisca’s six patents against other market participants. Companies manufacturing or distributing centrifugal mixing equipment for pharmaceutical compounding, personal care, or cannabis markets should conduct independent FTO analysis against this patent family.
PatSnap Eureka searches patents and litigation data to answer instantly.